SGMT · Sagimet Biosciences Inc. · Documents
$10.42
+0.86 (+9.00%)
At close · Oct 27
Return incl. dividend (before tax)
Market Cap
$599.83M
Shares
62.16M
Volume · Oct 27
1.11M
Avg daily vol (3M)
1.32M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Sagimet Biosciences Inc. dosed the first patient in its AURORA Phase 3 denifanstat acne trial in Oct 2026, with topline results expected in 2H 2027. | 2026-10-22 | — | |
| 8-K | Sagimet Biosciences Inc. agreed to an underwritten offering of 8,750,010 shares at $10.00 per share and pre-funded warrants for up to 2,750,010 shares at $9.9999 per share, expected to yield $107.5 million net and close October 1, 2026. | 2026-10-01 | 2026-09-30 | |
| 8-K | Sagimet reported positive 52-week ASC40-304 results for denifanstat, with 56.7% treatment success, 71.8% lower total lesions and 76.9% lower inflammatory lesions; AURORA screening was expected in October 2026. It also terminated its ATM Prospectus Supplement effective September 30, 2026. | 2026-09-30 | — | |
| 8-K | — | 2026-08-13 | — | |
| 8-K | — | 2026-08-11 | — | |
| 10-Q | — | 2026-08-11 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-08-11 | 2026-09-30 | |
| 8-K | — | 2026-07-21 | 2026-07-20 | |
| 8-K | — | 2026-06-12 | — | |
| 8-K | — | 2026-06-03 | 2026-05-28 | |
| 10-Q | — | 2026-05-12 | 2026-03-31 | |
| 8-K | — | 2026-05-12 | — | |
| 8-K | — | 2026-04-28 | 2026-04-27 | |
| 8-K | — | 2026-04-27 | — | |
| 8-K | — | 2026-04-27 | — | |
| DEF 14A | — | 2026-04-21 | 2026-06-12 | |
| ARS | — | 2026-04-21 | 2025-12-31 | |
| 8-K | — | 2026-04-21 | 2026-04-20 | |
| 10-K | — | 2026-03-11 | 2025-12-31 | |
| 8-K | — | 2026-03-11 | — | |
| 8-K | — | 2026-02-02 | — | |
| 8-K | — | 2025-12-18 | — | |
| 8-K | — | 2025-12-17 | — | |
| 10-Q | — | 2025-11-13 | 2025-09-30 | |
| 8-K | — | 2025-11-13 | — | |
| 8-K | — | 2025-10-23 | — | |
| 8-K | — | 2025-08-22 | 2025-08-18 | |
| 8-K | — | 2025-08-14 | — | |
| 10-Q | — | 2025-08-13 | 2025-06-30 | |
| 8-K | — | 2025-08-13 | — | |
| 8-K | — | 2025-06-10 | 2025-06-06 | |
| 8-K | — | 2025-06-04 | — | |
| 8-K | — | 2025-05-08 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| 8-K | — | 2025-04-30 | 2025-04-29 | |
| DEF 14A | — | 2025-04-30 | 2025-06-09 | |
| ARS | — | 2025-04-30 | 2024-12-31 | |
| 10-K | — | 2025-03-12 | 2024-12-31 | |
| 8-K | — | 2025-03-12 | — | |
| 8-K | — | 2025-03-11 | — | |
| 8-K | — | 2025-02-14 | — | |
| 8-K | — | 2025-01-02 | — | |
| 8-K | — | 2024-11-14 | — | |
| 10-Q | — | 2024-11-14 | 2024-09-30 | |
| 8-K | — | 2024-08-16 | 2024-08-15 | |
| S-3 | — | 2024-08-15 | — | |
| 10-Q | — | 2024-08-14 | 2024-06-30 | |
| 8-K | — | 2024-08-14 | — | |
| 8-K | — | 2024-08-01 | 2024-07-30 | |
| 8-K | — | 2024-07-02 | — |
Showing 1–50 of 83 filings
Key facts
CIK
1400118
CUSIP
786700104
13F (30d)
13 filings
13 filers
Visit website
Investor relations